Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:4 Number:163 ISSN#:2563-5476
ACE Report #4367
Ace Report Cover Pediatric Orthopaedics

Canakinumab effective in treating systemic juvenile idiopathic arthritis

How to Cite

OrthoEvidence. Canakinumab effective in treating systemic juvenile idiopathic arthritis. ACE Report. 2013;2(4):163. Available from: https://myorthoevidence.com/AceReport/Report/4367

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

N Engl J Med. 2012 Dec 20;367(25):2396-406. doi: 10.1056/NEJMoa1205099

Contributing Authors: N Ruperto HI Brunner P Quartier T Constantin N Wulffraat G Horneff R Brik L McCann O Kasapcopur L Rutkowska-Sak R Schneider Y Berkun I Calvo M Erguven L Goffin M Hofer T Kallinich SK Oliveira Y Uziel S Viola K Nistala C Wouters

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


177 patients, suffering from systemic juvenile idiopathic arthritis (JIA) with active systemic features, who had been chosen to participate in two trials between July 2009 and December 2010, were randomised into two groups to either receive canakinumab or a placebo. Patients in Trial 1 received either canakinumab or the placebo for 29 days. Trial 2 incorporated a two-part withdrawal design, which ...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.